The U.S. Food and Drug Administration (FDA) approves Leqembi (lecanemab) as a subcutaneous injection option to begin Alzheimer’s treatment, according to reporting from Investing.com. The approval covers use of Leqembi administered under the skin, rather than relying on an intravenous route, for patients starting therapy. The reports indicate the approval is specifically for initiation of Alzheimer’s treatment, expanding the way clinicians can deliver the medicine. The sources do not provide additional detailed trial results, safety findings, or specific patient criteria in the provided excerpts. No additional outlet perspectives are included here, so the summary reflects only the shared information available: that the FDA grants approval for a subcutaneous formulation of Leqembi and that this is intended to support initiation of treatment. The approval is presented as a development affecting clinical administration practices for Alzheimer’s care in the United States, with the main change being the route of administration.